A Multi-center, Randomized, Double-blind, Parallel, Active-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of 'GLA5PR GLARS-NF1 Tab.' and 'Pregabalin' in Peripheral Neuropathic Pain
Phase of Trial: Phase III
Latest Information Update: 09 May 2018
At a glance
- Drugs Pregabalin (Primary)
- Indications Neuropathic pain
- Focus Registrational; Therapeutic Use
- Sponsors Daewon Pharmaceutical
- 09 May 2018 According to a GL PharmTech media release, data are expected during the second half of this year.
- 09 May 2018 According to a GL PharmTech media release, last patient out in this trial on 18th April 2018.
- 21 Jul 2017 New trial record